Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Sentiment Report

Sentiment for Enanta Pharmaceuticals Inc (NASDAQ:ENTA)

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) institutional sentiment decreased to 1.5 in 2018 Q2. Its down -0.16, from 1.66 in 2018Q1. The ratio has dropped, as 93 hedge funds increased or opened new equity positions, while 62 sold and decreased equity positions in Enanta Pharmaceuticals Inc. The hedge funds in our partner’s database now possess: 14.64 million shares, up from 14.18 million shares in 2018Q1. Also, the number of hedge funds holding Enanta Pharmaceuticals Inc in their top 10 equity positions was flat from 2 to 2 for the same number . Sold All: 16 Reduced: 46 Increased: 59 New Position: 34.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.45 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 18.83 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

The stock decreased 2.07% or $1.57 during the last trading session, reaching $74.45. About 295,448 shares traded or 8.75% up from the average. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 110.33% since December 7, 2017 and is uptrending. It has outperformed by 94.71% the S&P500.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on February, 6. They expect $1.64 EPS, up 110.26 % or $0.86 from last year’s $0.78 per share. ENTA’s profit will be $31.85M for 11.35 P/E if the $1.64 EPS becomes a reality. After $1.30 actual EPS reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 26.15 % EPS growth.

Krensavage Asset Management Llc holds 15.36% of its portfolio in Enanta Pharmaceuticals, Inc. for 519,035 shares. Armistice Capital Llc owns 124,000 shares or 0.94% of their US portfolio. Moreover, Bogle Investment Management L P De has 0.83% invested in the company for 98,631 shares. The California-based Farallon Capital Management Llc has invested 0.77% in the stock. Granahan Investment Management Inc Ma, a Massachusetts-based fund reported 100,670 shares.

Since January 1, 0001, it had 0 buys, and 6 sales for $8.08 million activity.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.